REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

06 نوفمبر 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2024 Financial and Operating Results

31 أكتوبر 2024 06:30:01 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

24 أكتوبر 2024 08:00:04 بحسب Nasdaq GlobeNewswire

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18 أكتوبر 2024 17:05:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27 سبتمبر 2024 09:35:08 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27 سبتمبر 2024 07:00:04 بحسب Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

20 سبتمبر 2024 07:45:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

13 سبتمبر 2024 12:15:28 بحسب Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

11 سبتمبر 2024 07:00:46 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

11 سبتمبر 2024 01:04:00 بحسب Nasdaq GlobeNewswire

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

11 سبتمبر 2024 00:59:00 بحسب Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

09 سبتمبر 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

09 سبتمبر 2024 07:00:17 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

27 أغسطس 2024 10:44:05 بحسب NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 أغسطس 2024 13:12:44 بحسب NetDania Notify

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

26 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

26 أغسطس 2024 01:00:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 أغسطس 2024 09:56:19 بحسب NetDania Notify

Regeneron Provides Update on Biologics License Application for Linvoseltamab

20 أغسطس 2024 18:45:05 بحسب Nasdaq GlobeNewswire